national stem-cell therapy logo

Exploring the Frontier of Stem Cell Technology: Century Therapeutics’ Latest Breakthroughs at ASGCT 2024

Help Spread The Word, Share Post:

Century Therapeutics is making significant strides in the field of stem cell therapy, particularly with their induced pluripotent stem cell (iPSC) technology, which was showcased at the 2024 ASGCT Annual Meeting.

The company presented compelling preclinical data, emphasizing advancements in treating autoimmune diseases and enhancing the survivability of allogeneic cell therapies against natural killer (NK) cell rejection.

Their lead candidate, CNTY-101, an iPSC-derived NK cell therapy, demonstrates promising efficacy in targeting B-cells for the treatment of autoimmune conditions like systemic lupus erythematosus (SLE). This treatment leverages a CD19-specific mechanism that could lead to long-term remission by effectively depleting B-cells while maintaining safety and tolerability.

Furthermore, Century introduced a novel approach to protect stem cell-derived therapies from immune rejection. By using a synthetic ligand that targets CD300a—a receptor on NK cells—they could potentially enhance the compatibility and efficacy of stem cell therapies across various patients, a breakthrough in improving treatment outcomes in hematologic malignancies and beyond.

This pioneering work not only underscores Century’s role in advancing stem cell therapy but also promises a new era of treatment options that are more accessible, effective, and adaptable to a broad range of diseases. The ongoing development of their Allo-Evasion™ technology is set to redefine the standards for stem cell therapies, aiming for broader application and improved patient outcomes.

*** All content on NationalStemCellTherapy.com is for informational purposes only. All medical questions and concerns should always be consulted with your licensed healthcare provider.

Stay Connected

More Updates